| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Tuhura Biosciences, Inc./nv (HURA) has 2 insiders with recent SEC Form 4 filings, including 14 buys and 0 sells. HURA is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 610.3K | $1.45M | - | |
| CFO | 273.7K | $651.4K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 15, 2022 | Hoffman Robert E. | President And CEO | Buy | 55,000 | $0.47 | $25,795.00 | New | -65.1% | -74.0% | |
| Dec 8, 2021 | Praill Anthony Scott | Chief Financial Officer | Buy | 28,700 | $0.68 | $19,429.90 | +338.2% | -50.8% | -63.7% | |
| Dec 7, 2021 | Zarrabian Saiid | Head Of Strategic Partnerships | Buy | 50,000 | $0.63 | $31,316.37 | +218.4% | -48.4% | -68.4% | |
| Nov 22, 2021 | Johnson Laura L. | Director | Buy | 3,000 | $0.74 | $2,226.90 | New | -47.4% | -89.7% | |
| Aug 19, 2020 | Liatos John | SVP, Business Development | Buy | 196,750 | $0.00 | - | New | - | - | |
| Aug 19, 2020 | Murphy Keith | Director | Buy | 181,010 | $0.00 | - | New | - | - | |
| Sep 13, 2019 | Bell John K | Director | Buy | 35,000 | $0.68 | $23,744.00 | +360.8% | - | - | |
| Nov 16, 2017 | Bell John K | Director | Buy | 20,000 | $0.81 | $16,200.00 | +13.2% | - | - | |
| Nov 14, 2017 | Zarrabian Saiid | Interim CEO | Buy | 60,900 | $0.82 | $50,056.00 | New | - | - | |
| Oct 6, 2017 | Bacha Jeffrey | CEO | Buy | 10,000 | $0.87 | $8,724.50 | +8.7% | - | - |